ArticleClinical and translational radiation oncology2026
Impact of modern central nervous system radiation on multiple sclerosis relapse and progression.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central nervous system (CNS) radiation is associated with primary demyelination and neurotoxicity in patients with existing demyelinating disorders. We examined the safety of modern ionizing-radiation techniques in multiple-sclerosis (MS) patients. Patients and methods: Patients with MS undergoing CNS radiation for any reason between January 2005, and August 2024 were identified by chart review. Inclusion criteria were: 1) confirmed diagnosis of MS; 2) Receiving therapeutic radiation with a dose of greater than 5 Gray (Gy) to brain or spinal cord parenchyma; 3) Clinical neurology and brain MRI follow-up available following radiation. Results: Thirty-three patients were included. Median age at radiation was 60 years (54--68 IQR) and median follow-up, 20 months (range 3-99). Radiation focused on the CNS in 15/33 (45%), 5 (15%) targeted locations adjacent to the CNS parenchyma (meningioma 4, trigeminal neuralgia 1), and 13 (39%), outside the CNS with > 5 Gy delivered to the CNS. Clinical MS course at radiation was relapsing remitting (19/33), secondary progressive (11/33), and primary progressive (3/33). Thirteen patients (39%) were on MS disease-modifying therapy. No clinical relapse or new-onset MS progression followed radiation. New T2 or gadolinium-enhancing lesions on T1 MRI occurred in 7/33. Radiation-field data were analysed with reference to location of 10 new demyelinating lesions in 7 patients. Most lesions lay outside the irradiated area (6/10). No patients with new lesions were on high-efficacy medications. Seven patients experienced increased expanded disability status scale (EDSS) pre-radiation to last follow-up by ≥ 1 point (median 1.5, range 1-7). One patient had known progressive disease while 5 patients' increased disability was thought secondary to their radiation indication (3 glioblastoma and 2 meningioma). Conclusions: Modern-day ionizing radiation to the CNS in patients with multiple sclerosis was not associated with clinical worsening but can potentially be associated with an increased risk of asymptomatic inflammatory MS disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.